Avalo Therapeutics AVTX
Avalo Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$7.12+5.48%close on Oct. 28, 2026 · volume 2.2M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 16, 2026 | Christopher Ryan Sullivan Chief Financial Officer | Sold 10b5-1 plan | 12,394 | $16.33 | $202,437 |
| Sept. 10, 2026 | Christopher Ryan Sullivan Chief Financial Officer | Sold 10b5-1 plan | 10,185 | $17.62 | $179,457 |
| Aug. 28, 2026 | Mittie Doyle Chief Medical Officer | Sold 10b5-1 plan | 679 | $20.00 | $13,580 |
| Aug. 18, 2026 | Christopher Ryan Sullivan Chief Financial Officer | Sold 10b5-1 plan | 31,031 | $20.05 | $622,324 |
| Aug. 17, 2026 | Christopher Ryan Sullivan Chief Financial Officer | Sold 10b5-1 plan | 41,694 | $19.86 $19.85-$19.94 | $828,096 |
| Aug. 17, 2026 | Mittie Doyle Chief Medical Officer | Sold 10b5-1 plan | 1,000 | $20.00 | $20,000 |
| Aug. 11, 2026 | Jennifer Riley Chief Strategy Officer | Sold | 2,655 | $19.59 | $52,012 |
| Aug. 10, 2026 | Mittie Doyle Chief Medical Officer | Sold 10b5-1 plan | 679 | $20.00 | $13,580 |
| July 27, 2026 | Mittie Doyle Chief Medical Officer | Sold 10b5-1 plan | 1,000 | $20.00 | $20,000 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.